Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Mereo BioPharma Group (MREO) Non Operating Investment Income: 2018-2024

Historic Non Operating Investment Income for Mereo BioPharma Group (MREO) over the last 7 years, with Dec 2024 value amounting to -$419,000.

  • Mereo BioPharma Group's Non Operating Investment Income rose 432.20% to $196,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $668,000, marking a year-over-year increase of 186.64%. This contributed to the annual value of -$419,000 for FY2024, which is 271.02% down from last year.
  • Per Mereo BioPharma Group's latest filing, its Non Operating Investment Income stood at -$419,000 for FY2024, which was down 271.02% from $245,000 recorded in FY2023.
  • In the past 5 years, Mereo BioPharma Group's Non Operating Investment Income ranged from a high of $54.0 million in FY2021 and a low of -$141.1 million during FY2020.
  • For the 3-year period, Mereo BioPharma Group's Non Operating Investment Income averaged around $3.0 million, with its median value being $245,000 (2023).
  • In the last 5 years, Mereo BioPharma Group's Non Operating Investment Income plummeted by 12,726.03% in 2020 and then spiked by 138.26% in 2021.
  • Mereo BioPharma Group's Non Operating Investment Income (Yearly) stood at -$141.1 million in 2020, then soared by 138.26% to $54.0 million in 2021, then crashed by 82.80% to $9.3 million in 2022, then slumped by 97.36% to $245,000 in 2023, then plummeted by 271.02% to -$419,000 in 2024.